PharmTech News

Articles

Valneva will supply the UK government with an initial 60 million doses of the vaccine in the second half of 2021, if successful, and will provide more doses thereafter. 

Valneva Enters into $1.6-Billion Partnership with UK Government for COVID-19 Vaccine

The acquisition will give Gilead access to an anti-cancer antibody drug conjugate in clinical development for treating breast and bladder cancers. 

Gilead to Acquire Immunomedics for $21 Billion

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The White House issued an executive order Sunday, Sept. 13, 2020 implementing a policy to link payments for medicines provided through Medicare to prices charged in other industrial countries. 

Trump Escalates Drug Pricing War

In an opinion article, FDA leaders commit to applying “the best science” to approval decisions.

Career FDA Leaders Say Science Is Agency’s Guide

Takeda is divesting its portfolio of select, non-core prescription pharmaceutical products sold in Europe and Canada to Cheplapharm, a German pharmaceutical company.

Takeda to Divest Non-Core Assets for $562 million

As public confidence in the drug development process waivers, leading vaccine developers promise to adhere to scientific and regulatory principles.

Vaccine Developers Pledge to Stand with Science

The guidance recommends steps to detect and prevent nitrosamine impurities in pharmaceutical products.

FDA Publishes Guidance on Control of Nitrosamines 

The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.

Nestlé Health Science to Acquire Aimmune Therapeutics for $2.6 Billion

The transaction will give Ionis access to Akcea's pipeline and commercial products, as well as its cash on hand of approximately $390 million.

Ionis to Acquire Akcea Common Stock for $500 Million

FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data. 

Top News